Journal
INFLAMMOPHARMACOLOGY
Volume 28, Issue 6, Pages 1457-1476Publisher
SPRINGER BASEL AG
DOI: 10.1007/s10787-020-00757-9
Keywords
Inflammation; Rheumatology; JAK-STAT; IL-17; HIF
Categories
Funding
- SERB, GOI, New Delhi
- DHR-HRD, GOI, New Delhi
Ask authors/readers for more resources
Rheumatoid arthritis (RA), a multifactorial disease characterized by synovitis, cartilage destruction, bone erosion, and periarticular decalcification, finally results in impairment of joint function. Both genetic and environmental factors are risk factors in the development of RA. Unwanted side effects accompany most of the current treatment strategies, and around 20-40% of patients with RA do not clinically benefit from these treatments. The unmet need for new treatment options for RA has prompted research in the development of novel agents acting through physiologically and pharmacologically relevant targets. Here we discuss in detail three critical pathways, Janus kinase/signal transducer and activator of transcription (JAK/STAT), Th17, and hypoxia-inducible factor (HIF), and their roles as unique therapeutic targets in the field of RA. Some of the less developed but potential targets like nucleotide-binding and oligomerization domain-like receptor containing protein 3 (NLRP3) inflammasome and histone deacetylase 1 (HDAC1) are also discussed.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available